Cutaneous Manifestations in Non-Hodgkin’s Lymphoma

Mandal, Shramana; Varma, Kachnar; Jain, Shyama

doi:10.1159/000325860

Cited by 9 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The spectrum of skin lesions in oncohematologic patients is large and heterogeneous . In our series, immune‐mediated manifestations represented the most significant affection.…”

Section: Discussionmentioning

confidence: 69%

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department

Merlo

Cozzani

Canale

et al. 2018

Hematological Oncology

View full text Add to dashboard Cite

In recent years, dermatologic manifestations in oncohematologic patients have become more common. The aim of our study was to determine the incidence and heterogeneity of skin manifestations in patients followed at our Hematology Department. This observational monocentrical study was conducted on 60 patients. We divided the observed conditions in exanthematous, purpuric, vesicular‐bullous, papulonodular, urticarial, and eczematous manifestations. Moreover, all lesions were classified according to pathogenesis, in (a) specific skin manifestations, caused by neoplastic skin infiltration; (b) immune‐mediated manifestations, based on immunological mechanisms; and (c) skin lesions due to immunodeficiency. Altogether, 73 clinical manifestations were reported. Specific manifestations (a) were detected in 15.1% of the cases, mainly with papulonodular appearance. Immune‐mediated manifestations (b) were found in 37 cases (50.7%), particularly with eczematous or exanthematous appearance, and leukemia was the malignancy most frequently reported in these patients. Eventually, lesions due to immunosuppression (c) were reported in 34.2% of the cases. They were represented by infections and cutaneous malignancies, and usually manifested with papulonodular lesions. Skin lesions in oncohematologic patients are a common event. A multidisciplinary approach based on the collaboration between the hematologist and the dermatologist is crucial to achieve a proper diagnosis, and correctly manage these manifestations.

show abstract

“…The spectrum of skin lesions in oncohematologic patients is large and heterogeneous . In our series, immune‐mediated manifestations represented the most significant affection.…”

Section: Discussionmentioning

confidence: 69%

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department

Merlo

Cozzani

Canale

et al. 2018

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Specific cutaneous lesions in patients affected by a systemic NHL are uncommon, involving about 13–20% of patients and are characterized by the presence of neoplastic elements in the skin. These cells can reach cutaneous layers by three possible mechanisms: lymphatic retrograde diffusion, haematological diffusion or contiguity .…”

Section: Specific Lesionsmentioning

confidence: 99%

“…Clinical aspects are polymorphous, with different cutaneous appearance: red lesions as papules, nodules, plaques, usually associated with ulcerations and erythrodermic states . Their presence is correlated with the clinical evolution of lymphoma and a poorer prognosis, due to the more aggressive behaviour of the disease . Specific manifestations are less frequent than non‐specific ones because the skin is not a frequent site of early metastasis in course of systemic malignancies, but represents a site of late metastasis probably caused by a late‐staging malignancy with a lot of neoplastic cells in systemic circulation .…”

Section: Specific Lesionsmentioning

confidence: 99%

“…In literature, dermatological affections have been described in 50% of patients affected by NH systemic lymphomas . Despite this high frequency, the majority of published information has been in the form of case reports or series of small numbers of patients, and did not analyse the overall components of this topic, thereby producing a fragmented puzzle of information.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous manifestations of systemic non‐Hodgkin lymphomas (NHL): study and review of literature

Carlesimo¹,

Narcisi²,

Rossi

et al. 2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

Systemic non-Hodgkin lymphomas are often accompanied by cutaneous manifestations, which are not always looked out for. Nevertheless, these alterations can be very important because their presence is lied to the clinical behaviour of the underlying malignancy, with an early recognition being fundamental. The aim of this study was to make order in this topic and propose a preliminary classification of the cutaneous manifestations associated with non-Hodgkin lymphomas. We performed a retrospective chart review of 62 haematological patients affected by non-Hodgkin systemic lymphomas with dermatological manifestations, who were evaluated from January 2007 to December 2011, and combined these results with a systematic review of Pub medical literature from 1937 to 2011 on this topic. A preliminary classification of these manifestations has been proposed, dividing them in specific and non-specific ones, along with a description of the clinical features and those cases observed in our department. A preliminary approach has been proposed for the study of these manifestations that could be helpful in understanding the biological behaviour and aid early recognition of a flare up in systemic non-Hodgkin lymphomas.

show abstract

“…Eine ähnliche Studie, in der 12 813 Patienten mit chronischem Juckreiz begleitet wurden, ermittelte im Vergleich zur Allgemeinbevölkerung einen Anstieg der Inzidenz von Krebserkrankungen um insgesamt 13% und von hämatologischen Krebserkrankungen um 68% über einen Zeitraum von 5 Jahren [5]. Paraneoplastischer Pruritus kommt am häufigsten bei lymphoproliferativen malignen Erkrankungen vor, unter anderem bei multiplem Myelom, Non-Hodgkin-Lymphomen (15% Prävalenz) und Hodgkin-Lymphomen (25% Prävalenz) [6,7,8]. …”

Section: Definition Und Klinische Merkmaleunclassified

Management von paraneoplastischem Pruritus

Rowe¹,

Yosipovitch²

2018

Kompass Dermatol

View full text Add to dashboard Cite

Paraneoplastischer Pruritus tritt als systemische Reaktion auf eine zugrunde liegende maligne Erkrankung auf. Paraneoplastischer Pruritus ist am häufigsten mit malignen lymphoproliferativen Erkrankungen sowie soliden Tumoren, die zu Cholestase führen, assoziiert. Paraneoplastischer Pruritus kann sich sowohl ohne primären Hautausschlag manifestieren als auch in Verbindung mit dermatologischen Erkrankungen wie Erythrodermie, Acanthosis nigricans, Dermatomyositis (DM), transitorischer akantholytischer Dermatose (Morbus Grover) oder eruptiver seborrhoischer Keratose. Die Behandlung des paraneoplastischen Pruritus beruht primär auf der Behandlung der zugrunde liegenden malignen Erkrankung, die ursächlich für die systemische Reaktion ist. Wenn die maligne Erkrankung nicht auf Behandlung anspricht, können andere Therapien beim paraneoplastischen Pruritus wirksam sein, wie selektive Serotonin-Wiederaufnahmehemmer, Mirtazapin, Gabapentin, Thalidomid, Opioide, Aprepitant und Histon-Deacetylase-Inhibitoren. Übersetzung aus Curr Probl Dermatol. Basel, Karger, 2016, vol 50, pp 149-154 (DOI: 10.1159/000446060)

show abstract

Cutaneous Manifestations in Non-Hodgkin’s Lymphoma

Cited by 9 publications

References 14 publications

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department

Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department

Cutaneous manifestations of systemic non‐Hodgkin lymphomas (NHL): study and review of literature

Management von paraneoplastischem Pruritus

Contact Info

Product

Resources

About